Funding agencies: This study was sponsored by the National Institute of Neurological Disorders and Stroke (U01NS050095), Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program (W23RRYX7022N606), Parkinson's Disease Foundation, Cephalon Inc, and Lundbeck A/S.
Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments
Article first published online: 9 OCT 2013
© 2013 Movement Disorder Society
Volume 28, Issue 14, pages 1980–1986, December 2013
How to Cite
Lang, A. E., Eberly, S., Goetz, C. G., Stebbins, G., Oakes, D., Marek, K., Ravina, B., Tanner, C. M., Shoulson, I. and on behalf of the LABS-PD investigators (2013), Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. Mov. Disord., 28: 1980–1986. doi: 10.1002/mds.25671
Relevant conflicts of interest/financial disclosures: Drs. Lang, Goetz and Stebbins served on the Movement Disorder Society Development Committee of the MDS-UPDRS.
Full financial disclosures and author roles may be listed in the online version of this article.
See Appendix for list of LABS-PD Investigators.
- Issue published online: 9 DEC 2013
- Article first published online: 9 OCT 2013
- Manuscript Accepted: 29 JUL 2013
- Manuscript Revised: 22 JUL 2013
- Manuscript Received: 14 MAR 2013
- Parkinson's disease;
- rating scales
The Movement Disorder Society (MDS) commissioned a revision of the UPDRS with the goals of improving instructions and definitions, more accurately evaluating milder features, and assessing patient-reported outcomes and nonmotor features. To date, no study has evaluated longitudinal changes in components of the MDS-UPDRS over time or correlated these with changes in other scales of various symptoms. We assessed Parts I and II of the MDS-UPDRS (non-Motor and Motor Experiences of Daily Living [nM-EDL, M-EDL]) as well as a number of other scales of motor, cognitive and behavioral function in a large population of patients (n = 383) with early- to mid-stage Parkinson's disease (PD) who had previously participated in a trial of a putative disease-modifying agent. Both parts of a MDS-UPDRS showed significant change over the 3-year follow-up period, with M-EDL scores declining to a greater extent than nM-EDL. Both the scores and their changes over time correlated relatively well with other rating scales of similar disease aspects. Modest correlations with the original version of the UPDRS supported the increased attention to nonmotor symptoms as well as milder levels of severity in the MDS-UPDRS. The M-EDL was much more sensitive to change over time in these early- to mid-stage patients than the original UPDRS Activities of Daily Living (ADL) scale. Finally, we showed no change over time in a small group of individuals with dopamine transporter single-photon emission computed tomography scans without evidence for dopamine deficiency. The nM-EDL and M-EDL components of the MDS-UPDRS provide an effective, relevant measure of change in the broad spectrum of symptoms of PD over the first decade of the disease. © 2013 International Parkinson and Movement Disorder Society